Pieris Pharmaceuticals. has filed a patent for methods to predict positive clinical outcomes in cancer patients treated with a 4-1BB agonistic agent. The method involves measuring soluble 4-1BB levels before and after treatment to determine efficacy. This innovation could revolutionize cancer treatment. GlobalData’s report on Pieris Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Pieris Pharmaceuticals, Active contour based diagnosis models was a key innovation area identified from patents. Pieris Pharmaceuticals's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Predicting positive cancer patient outcomes with 4-1bb agonistic agent
See Also:
A recently filed patent (Publication Number: US20230366884A1) outlines a method for predicting a positive clinical outcome for cancer patients undergoing treatment with a 4-1BB agonistic agent. The method involves measuring the level of soluble 4-1BB (s4-1BB) in biological samples obtained from the patient before and after administering the agent. An increase in s4-1BB levels post-treatment indicates a positive clinical outcome, which can include stable disease, partial response, complete response, increased overall survival, and increased progression-free survival. Additionally, the patent describes methods for assessing the activity of the 4-1BB agonistic agent in patients, selecting appropriate doses based on s4-1BB levels, and using s4-1BB as a predictive biomarker for treatment outcomes.
Furthermore, the patent discusses the use of s4-1BB as a biomarker for activity and dose-dependent activity of the 4-1BB agonistic agent, as well as for selecting optimal treatment doses. It also includes the use of kits for detecting s4-1BB in biological samples to predict clinical outcomes and assess treatment activity. The patent details the measurement of s4-1BB levels during multiple treatment cycles and emphasizes the importance of monitoring s4-1BB levels to ensure treatment efficacy. Overall, the patent provides a comprehensive framework for utilizing s4-1BB as a predictive and diagnostic tool in cancer treatment, particularly in conjunction with 4-1BB agonistic agents.
To know more about GlobalData’s detailed insights on Pieris Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
